TABLE 1

Patient and Tumor Characteristics

Patient no.	Initial presentation			Age (y)	Final status	¹⁸F-FDG PET foci			Molecular imaging technique	Additional foci on ¹⁸F-FDG PET, compared with…^*		Germline mutation
Patient no.	Initial presentation	Indication	Sex	Age (y)	Final status	¹⁸F-FDG PET foci	VA	SUVmax	Molecular imaging technique	SPECT	FDOPA	Germline mutation
1	Pheo	Initial staging	F	58	Unifocal	Adrenal	Pos	3.5	MIBG	No (=)	ND	Absent
2	Pheo	Initial staging	F	30	Unifocal	Adrenal	Pos	12	MIBG	No (=)	ND	Absent
3	Pheo	Initial staging	M	38	Unifocal	Adrenal	Pos	11	FDOPA	ND	No (=)	Absent
4	Pheo	Initial staging	M	30	Unifocal	Adrenal	Neg	2.1	MIBG, FDOPA	No (=)	No (<)	Absent
5	Pheo	Initial staging	F	26	Unifocal	Adrenal	Pos	9.5	MIBG	No (=)	ND	Absent
6	Ab PGL	Initial staging	M	64	Unifocal	Ab PGL	Pos	4.5	MIBG	No (=)	ND	Absent
7	Ab PGL	Initial staging	F	52	Unifocal	Ab PGL	Pos	5.7	MIBG, FDOPA, SRS	No (=)	No (=)	Absent
8	Pheo	Initial staging	F	30	Unifocal	Adrenal	Pos	3.8	FDOPA	—	ND	Absent
9	Pheo	Initial staging	M	34	Unifocal	Adrenal	Pos	42	MIBG	No (=)	ND	SDHB
10	Pheo	Recurrence	M	25	Multifocal	Adrenal, ab PGL (renal pedicle)	Pos	6	MIBG, FDOPA, SRS	Yes	No (=)	VHL
11	Pheo + PGL	Initial staging	M	34	Multifocal	Ab and ce PGL (gl)	Pos	21	MIBG, FDOPA, SRS	Yes	Yes	SDHD
12	Ce PGL	Initial staging	M	67	Multifocal	Ce PGL (gl + vagal)	Pos	3.5	SRS, FDOPA	No (=)	No (=)	Absent
13	Pheo	Recurrence	M	70	Multifocal	Ce PGL (gl)	Pos	5.3	MIBG, FDOPA, SRS	No (=)	No (=)	SDHB
14	Pheo + PGL	Recurrence	M	56	Multifocal	Ab PGL	Pos	3.9	MIBG	Yes	ND	ND
15	Pheo	Initial staging	M	36	Multifocal	Adrenal (bilateral)	Pos	3.7	MIBG	No (=)	ND	Absent
16	Pheo	Initial staging	M	51	Unifocal	Adrenal	Pos	4.7	MIBG	No (=)	ND	NF1
17	Pheo	Initial staging	M	45	Unifocal	Adrenal	Neg	1.9	MIBG, FDOPA	No (=)	No (<)	NF1
18	Pheo	Recurrence	M	35	Multifocal	Adrenal	Pos	2	MIBG	No (=)	ND	RET
19	Pheo	Recurrence	F	61	Metastatic	Lung, me, carcinosis	Pos	4.5	MIBG, FDOPA	Yes	No (=)	Absent
20	Pheo	Recurrence	M	75	Metastatic	Adrenal, Lung, me, liver, LN	Pos	13.3	MIBG, FDOPA	Yes	Yes	Absent
21	Pheo	Recurrence	F	32	Metastatic	Lung, liver, bone	Pos	2.3	MIBG, FDOPA	Yes	No (<)	Absent
22	Pheo	Recurrence	M	34	Metastatic	Liver, bone	Pos	9.9	MIBG, FDOPA, HMDP	No (<)	No (<)	Absent
23	Pheo	Recurrence	M	43	Metastatic	Lung, liver, LN	Pos	3.3	MIBG, FDOPA, HMDP	Yes	No (<)	Absent
24	PGL	Recurrence	M	78	Metastatic	Ab PGL, bone	Pos	7	MIBG, FDOPA, HMDP	Yes	Yes	Absent
25	PGL	Recurrence	F	59	Metastatic	Lung, LN, Bone	Pos	3	MIBG, FDOPA, HMDP, SRS	Yes	No (<)	Absent
26	Pheo	Initial staging	M	63	Metastatic	Adrenal, Bone	Pos	7.8	MIBG, FDOPA	Yes	No (<)	ND
27	PGL	Recurrence	M	38	Metastatic	Ab and ce PGL, LN	Pos	29.3	MIBG, FDOPA	Yes	Yes	SDHB
28	Pheo	Initial staging	M	34	Metastatic	Adrenal, Bone	Pos	17	MIBG, HMDP	Yes	ND	SDHB

VA = visual analysis; FDOPA = 6-¹⁸F-fluorodopa PET; pheo = pheochromocytoma; pos = positive; MIBG = ¹³¹I-MIBG; ND = not done; ab = abdominal; PGL = paraganglioma; SRS = somatostatin receptor scintigraphy; ce = cervical; gl = glomic; neg = negative; RET = RET protooncogene; me = mediastinal; LN = lymph node; HMDP = ^99mTc-HMDP; HMDP = hydroxymethylenediphosphonate.
↵* Comparison between ¹⁸F-FDG PET and SPECT (¹³¹I-metaiodobenzylguanidine [MIBG] or SRS) and 6-¹⁸F-fluorodopa PET studies in terms of number of tumor sites. = indicates equivalent number of tumor sites on ¹⁸F-FDG PET; < indicates lower number of tumor sites on ¹⁸F-FDG PET; > indicates higher number of tumor sites on ¹⁸F-FDG PET.